Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Diluted Average) (2020 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $138875.0 in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 99.8% year-over-year to $138875.0; the TTM value through Dec 2025 reached $138875.0, down 99.8%, while the annual FY2025 figure was $138875.0, 99.8% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $138875.0 in Q4 2025 per VRDN's latest filing, down from $145160.0 in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $81.5 million in Q2 2025 and bottomed at $66385.0 in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $30.8 million, with a median of $28.1 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 102160.8% in 2024, then crashed 99.8% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $11.9 million in 2021, then skyrocketed by 169.22% to $32.1 million in 2022, then plummeted by 99.79% to $66385.0 in 2023, then surged by 102160.8% to $67.9 million in 2024, then plummeted by 99.8% to $138875.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $138875.0 in Q4 2025, $145160.0 in Q3 2025, and $81.5 million in Q2 2025.